I. Pires da Silva

发表

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

G. Mann, J. McQuade, J. Wilmott, 2019, Clinical Cancer Research.

Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies.

K. Shannon, R. Scolyer, G. Long, 2021, European journal of cancer.

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.

Stephen B. Fox, S. Prakash, K. Shannon, 2021, Pathology.

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites

K. Shannon, J. Wilmott, R. Scolyer, 2022, Journal for ImmunoTherapy of Cancer.

Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy

G. Long, S. Lo, A. Menzies, 2019, Cancer.

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

P. Ascierto, Douglas B. Johnson, G. Long, 2022, Journal for ImmunoTherapy of Cancer.

Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.

P. Ascierto, C. Blank, G. Long, 2020 .

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies

Douglas B. Johnson, L. Haydu, M. Millward, 2019, Pigment cell & melanoma research.

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

J. Wilmott, R. Scolyer, G. Long, 2022, Journal for ImmunoTherapy of Cancer.

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy

J. Wilmott, R. Scolyer, I. Pires da Silva, 2022, Frontiers in Immunology.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

L. Pickering, Douglas B. Johnson, C. Blank, 2022, European journal of cancer.

Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis

J. Wilmott, R. Scolyer, G. Long, 2022, JCI insight.

Comprehensive analysis of cutaneous and uveal melanoma liver metastases

A. Broeks, T. Schumacher, R. Scolyer, 2020, Journal for ImmunoTherapy of Cancer.

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

J. Pearson, K. Shannon, G. Mann, 2021, Cancer cell.

Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.

P. Ascierto, G. Long, C. Lebbé, 2023, European journal of cancer.

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

M. Weichenthal, J. Utikal, D. Schadendorf, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.

Douglas B. Johnson, G. Long, O. Michielin, 2021, European journal of cancer.

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

J. Wilmott, R. Scolyer, G. Long, 2021, Cancers.

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

P. Ascierto, Douglas B. Johnson, C. Blank, 2021, The Lancet. Oncology.

CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.

D. Schadendorf, P. Ascierto, R. Amaria, 2022, The New England journal of medicine.

Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas

J. Pearson, G. Mann, N. Hayward, 2020, Cancer Immunology Research.

Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread

K. Shannon, R. Scolyer, G. Long, 2022, Melanoma research.

Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

J. Wilmott, R. Scolyer, G. Long, 2019, Clinical Cancer Research.

153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

M. Millward, H. Gan, J. Coward, 2021, Annals of Oncology.

Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma

J. Wilmott, R. Scolyer, I. Vergara, 2023, Pathology.

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

C. Berking, A. Hauschild, D. Schadendorf, 2021, Journal for ImmunoTherapy of Cancer.

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

J. Wilmott, R. Scolyer, A. Menzies, 2023, Oncoimmunology.

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies

J. Wilmott, R. Scolyer, S. Lo, 2023, Journal for ImmunoTherapy of Cancer.

Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy.

J. Wilmott, R. Scolyer, U. Palendira, 2024, Cell reports.

Exploiting temporal aspects of cancer immunotherapy.

V. Anagnostou, W. Lesterhuis, Rachael M. Zemek, 2024, Nature reviews. Cancer.

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

I. Pires da Silva, Jorja Braden, P. Serra-Bellver, 2024, European journal of cancer.

Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy.

R. Scolyer, A. Menzies, M. Carlino, 2023, European journal of cancer.